ESR1 and breast cancer: The phase II ELAINEII trial (NCT04432454) is evaluating the combination of lasofoxifene with abemaciclib in advanced or metastatic HR+/HER2− BC patients with an ESR1 mutation who had disease progression on first and/or second lines of treatment, such as ET plus CDK4/6i [226].